The objective of the current study was to determine the expression profiles of the Breast Cancer genes 1 and 2, two tumor suppressing genes, in patients with breast cancer in the Gbêkê region of C？te d’Ivoire. This cross-sectional study was carried from September 2023 to January 2025. The patients came from five screening and management sites for breast diseases in the Gbêkê region. Breast micro-biopsies were stored in an RNA Protect solution at ？80？C before processing. RNA extraction was performed with RNAEsy/Triazol kit from Qiagen. And RT-qPCR was carried out using specific primers and probes for BRCA1 and 2 mRNAs. Fifty-eight participants were recruited. Among which them, 43 had breast carcinoma and 15 had various non-malignant breast tumors. The average age of the participants was 42.9 ± 10.1 with ages ranging from 24 to 71 years. These women were mostly unemployed and/or not civil servants in 93% of the cases. Out of them, 9.3% used hormonal contraceptives, and 72.1% were premenopausal. The BRCA1 gene was expressed in 25.6% of carcinoma patients and 20.0% of the non-malignant participants. And its expression levels were low in both groups. The BRCA2 gene was expressed in 62.8% of carcinoma cases and 66.7% of the non-malignant cases. And its expression levels were high in both groups. Breast cancer is frequent in the Gbêkê region. It would therefore be wise to integrate the expression profile of BRCA1 and BRCA2 in all women from adolescence for rigorous monitoring of the disease.
References
[1]
Bray, F., Laversanne, M., Sung, H., Ferlay, J., Siegel, R.L., Soerjomataram, I., et al. (2024) Global Cancer Statistics 2022: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 74, 229-263. https://doi.org/10.3322/caac.21834
[2]
Toure, M., Nguessan, E., Bambara, A.T., Kouassi, Y.K.K., Dia, J.M.L. and Adoubi, I. (2013) Facteurs liés au diagnostic tardif des cancers du sein en Afrique-sub-saharienne: Cas de la Côte d’Ivoire. GynécologieObstétrique & Fertilité, 41, 696-700. https://doi.org/10.1016/j.gyobfe.2013.08.019
[3]
Horton, C., Cass, A., Conner, B.R., Hoang, L., Zimmermann, H., Abualkheir, N., et al. (2022) Mutational and Splicing Landscape in a Cohort of 43,000 Patients Tested for Hereditary Cancer. NPJ Genomic Medicine, 7, Article No. 49. https://doi.org/10.1038/s41525-022-00323-y
[4]
Szender, J.B., Kaur, J., Clayback, K., Hutton, M.L., Mikkelson, J., Odunsi, K., et al. (2018) Breadth of Genetic Testing Selected by Patients at Risk of Hereditary Breast and Ovarian Cancer. International Journal of Gynecological Cancer, 28, 26-33. https://doi.org/10.1097/igc.0000000000001122
[5]
Cohen-Haguenauer, O. (2019) Prédisposition héréditaire au cancer du sein (1)-Génétique. Médecine/Sciences, 35, 138-151.
[6]
Rosen, E.M., Fan, S., Pestell, R.G. and Goldberg, I.D. (2003) BRCA1 Gene in Breast Cancer. Journal of Cellular Physiology, 196, 19-41. https://doi.org/10.1002/jcp.10257
[7]
Esteller, M., et al. (2000) Promoter Hypermethylation and BRCA1 Inactivation in Sporadic Breast and Ovarian Tumors. Journal of the National Cancer Institute, 92, 564-569. https://doi.org/10.1093/jnci/92.7.564
[8]
Satyananda, V., Oshi, M., Endo, I. and Takabe, K. (2021) High BRCA2 Gene Expression Is Associated with Aggressive and Highly Proliferative Breast Cancer. Annals of Surgical Oncology, 28, 7356-7365. https://doi.org/10.1245/s10434-021-10063-5
[9]
Aka, E., Horo, A., Koffi, A., Fanny, M., Didi-Kouko, C., Nda, G., et al. (2021) Expérience africaine monocentrique de la prise en charge personnalisée des cancers du sein à Abidjan: Défis et perspectives. GynécologieObstétriqueFertilité & Sénologie, 49, 684-690. https://doi.org/10.1016/j.gofs.2021.03.001
[10]
Somé, O., Bagué, A., Konkobo, D., et al. (2022) Breast Cancer in Bobo-Dioulasso, Burkina Faso: Management Outcomes. Oncologie, 24, 173-184.
[11]
Togo, A., Traoré, A., Traoré, C., Dembélé, B.T., Kanté, L., Diakité, I., et al. (2010) Cancer du sein dans deux centres hospitaliers de Bamako (Mali): Aspects diagnostiques et thérapeutiques. African Journal of Cancer, 2, 88-91. https://doi.org/10.1007/s12558-010-0060-x
[12]
Recensement général de la population et de l’habitat. https://plan.gouv.ci/assets/fichier/RGPH2021-RESULTATS-GLOBAUX-VF.pdf
[13]
Ho-Pun-Cheung, A., Cellier, D. and Lopez-Crapez, E. (2008) La RT-qPCR en oncologie: Considérations pour la normalisation. Libbey-Eurotext, Montrouge, 2, 121-129.
[14]
Bong, D., Sohn, J. and Lee, S.V. (2024) Brief Guide to RT-qPCR. Molecules and Cells, 47, Article ID: 100141. https://doi.org/10.1016/j.mocell.2024.100141
[15]
Chen, L., Chen, Y., Xie, Z., Luo, J., Wang, Y., Zhou, J., et al. (2022) Comparison of Immunohistochemistry and RT-qPCR for Assessing ER, PR, HER2, and Ki67 and Evaluating Subtypes in Patients with Breast Cancer. Breast Cancer Research and Treatment, 194, 517-529. https://doi.org/10.1007/s10549-022-06649-6
[16]
Taron, M., Rosell, R., Felip, E., Mendez, P., Souglakos, J., Ronco, M.S., et al. (2004) BRCA1 mRNA Expression Levels as an Indicator of Chemoresistance in Lung Cancer. Human Molecular Genetics, 13, 2443-2449. https://doi.org/10.1093/hmg/ddh260
[17]
Essiben, F., Foumane, P., Mboudou, E.T., Dohbit, J.S., Koh, M.V. and Ndom, P. (2013) Diagnostic et traitement du cancer du sein au Cameroun à propos de 65 cas. Mali Medical, 28, 1-5. https://openurl.ebsco.com/contentitem/gcd:97251046?sid=ebsco:plink:crawler&id=ebsco:gcd:97251046
[18]
Ndiaye, M., Dieng, S., Thiam, J., Diallo, A.C., Diouf, D., Ka, S., et al. (2021) Evaluation des facteurs pronostiques dans le cancer du sein chez la femme au Sénégal: À propos de 288 cas. African Journal of Oncology, 1, 4-9. https://doi.org/10.54266/ajo.1.1.6.6
[19]
Gnangnon, F., Brun, L., Worou, C., Seidou, F., D’almeida, T., Amidou, S., et al. (2020) Âge du diagnostic des cancers du sein en République du Bénin (Afrique de l’Ouest): Pouvons-nous encore appliquer les standards occidentaux en matière de dépistage? Revue d’Épidémiologie et de Santé Publique, 68, S101. https://doi.org/10.1016/j.respe.2020.03.027
[20]
Comet, B., Cutuli, B., Penault-Llorca, F., Bonneterre, J. and Belkacémi, Y. (2009) Cancer du sein chez l’homme: revue de la littérature. Bulletin du Cancer, 96, 181-189. https://doi.org/10.1684/bdc.2008.0813
[21]
Institut National de la Statistique (INS) (s.d.) International. Enquête Dé-mographique et de Santé et à Indicateurs Multiples de Côte d’Ivoire 2011-2012. Institut National de la Statistique et ICF International, 512 p.
[22]
Family Planning (2020) Côte d’Ivoire: Preneur d’engagement depuis 2012. https://www.fp2030.org/fr/resources/resources-strong-alliances-further-together-country-engagement-fp2020-2012-2020/
[23]
Fouad, A., Akasbi, Y., Znati, K., El Mesbahi, O., Amarti, A. and Bennis, S. (2012) Molecular Classification of Breast Cancer in Morocco. Pan African Medical Journal, 13, Article No. 91.
[24]
Han, Y., Wang, J. and Xu, B. (2020) Clinicopathological Characteristics and Prognosis of Breast Cancer with Special Histological Types: A Surveillance, Epidemiology, and End Results Database Analysis. The Breast, 54, 114-120. https://doi.org/10.1016/j.breast.2020.09.006
[25]
Effi, A.B., Aman, N.A., Koui, B.S., Koffi, K.D., Traore, Z.C. and Kouyate, M. (2016) Breast Cancer Molecular Subtypes Defined by ER/PR and HER2 Status: Association with Clinicopathologic Parameters in Ivorian Patients. Asian Pacific Journal of Cancer Prevention, 17, 1973-1978. https://doi.org/10.7314/apjcp.2016.17.4.1973
[26]
Hill, D.A., Friend, S., Lomo, L., Wiggins, C., Barry, M., Prossnitz, E., et al. (2018) Breast Cancer Survival, Survival Disparities, and Guideline-Based Treatment. Breast Cancer Research and Treatment, 170, 405-414. https://doi.org/10.1007/s10549-018-4761-7
[27]
Rahman, W.T. and Helvie, M.A. (2022) Breast Cancer Screening in Average and High-Risk Women. Best Practice & Research Clinical Obstetrics & Gynaecology, 83, 3-14. https://doi.org/10.1016/j.bpobgyn.2021.11.007
[28]
Meadows, R.J., Figueroa, W., Shane-Carson, K.P. and Padamsee, T.J. (2022) Predicting Breast Cancer Risk in a Racially Diverse, Community-Based Sample of Potentially High-Risk Women. Cancer Medicine, 11, 4043-4052. https://doi.org/10.1002/cam4.4721
[29]
Goldhirsch, A., Winer, E.P., Coates, A.S., Gelber, R.D., Piccart-Gebhart, M., Thürlimann, B., et al. (2013) Personalizing the Treatment of Women with Early Breast Cancer: Highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Annals of Oncology, 24, 2206-2223. https://doi.org/10.1093/annonc/mdt303
[30]
Cheng, H.F., Tsai, Y.F., Liu, C.Y., et al. (2023) Breast Cancer Research, 25, Article No. 152. https://doi.org/10.1186/s13058-023-01751-z
[31]
Thompson, C., MacDonald, G. and Mueller, C.R. (2011) Decreased Expression of BRCA1 in SK-BR-3 Cells Is the Result of Aberrant Activation of the GABP Beta Promoter by an NRF-1-Containing Complex. Molecular Cancer, 10, Article No. 62. https://doi.org/10.1186/1476-4598-10-62
[32]
Oubaddou, Y., Oukabli, M., Fenniche, S., Elktaibi, A., Elochi, M.R., Al Bouzidi, A., et al. (2023) BRCA1 Promoter Hypermethylation in Malignant Breast Tumors and in the Histologically Normal Adjacent Tissues to the Tumors: Exploring Its Potential as a Biomarker and Its Clinical Significance in a Translational Approach. Genes, 14, Article No. 1680. https://doi.org/10.3390/genes14091680
[33]
Arif, T. and Anwar, N. (2020) Promoter Hypermethylation and Expression Changes of BRCA1 Gene in a Cohort of Sporadic Breast Cancer Cases among Pakistani Population. Asian Pacific Journal of Cancer Prevention, 21, 2395-2401. https://doi.org/10.31557/apjcp.2020.21.8.2395
[34]
Hasan, N.A. and Pity, I.S. (2023) BRCA1 Methylation in Breast Duct Carcinoma, a Practical Study in Duhok-Iraq. Cellular and Molecular Biology, 69, 34-39. https://doi.org/10.14715/cmb/2023.69.14.6
[35]
Lima, B.A., Pais, A.C., Dupont, J., Dias, P., Custódio, N., Sousa, A.B., et al. (2024) Genetic Modulation of RNA Splicing Rescues BRCA2 Function in Mutant Cells. Life Science Alliance, 8, e202402845. https://doi.org/10.26508/lsa.202402845
[36]
Zhang, Y., Wu, H., Yu, Z., Li, L., Zhang, J., Liang, X., et al. (2022) Germline Variants Profiling of BRCA1 and BRCA2 in Chinese Hakka Breast and Ovarian Cancer Patients. BMC Cancer, 22, Article No. 842. https://doi.org/10.1186/s12885-022-09943-0
[37]
Hayes, M.M. (2011) Adenomyoepithelioma of the Breast: A Review Stressing Its Propensity for Malignant Transformation. Journal of Clinical Pathology, 64, 477-484. https://doi.org/10.1136/jcp.2010.087718
[38]
Kumar, M., Sagar, M., Vimal, J.K. and Kumar, V. (2023) A Malignant Transformation of Borderline Phyllodes Tumor to Fibrosarcoma Breast: A Rare Case Report. Journal of Cancer Research and Therapeutics, 19, S892-S895. https://doi.org/10.4103/jcrt.jcrt_378_21
[39]
Diéras, V., Han, H.S., Kaufman, B., Wildiers, H., Friedlander, M., Ayoub, J., et al. (2020) Veliparib with Carboplatin and Paclitaxel in Brca-Mutated Advanced Breast Cancer (BROCADE3): A Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial. The Lancet Oncology, 21, 1269-1282. https://doi.org/10.1016/s1470-2045(20)30447-2
[40]
Geyer, C.E., Garber, J.E., Gelber, R.D., Yothers, G., Taboada, M., Ross, L., Rastogi, P., et al. (2022). Overall Survival in the OlympiA Phase III Trial of Adjuvant Olaparib in Patients with Germline Pathogenic Variants in BRCA1/2 and High-Risk, Early Breast Cancer. Annals of Oncology, 33, 1250-1268. https://doi.org/10.1016/j.annonc.2022.09.159..
